SynCore Biotechnology Co., Ltd. Statistics
SynCore Biotechnology Co., Ltd. (4192) Stock Statistics & Valuation Metrics
Total Valuation
SynCore Biotechnology Co., Ltd. has a market cap or net worth of TWD 541.63M. The enterprise value is TWD 571.78M.
- Market Cap
- TWD 541.63M
- Enterprise Value
- TWD 571.78M
Share Statistics
SynCore Biotechnology Co., Ltd. has 34,280,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 34,280,500
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
SynCore Biotechnology Co., Ltd.’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -19.05%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.18
- Return on Invested Capital (ROIC)
- -19.05%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 676.08K
- Profits Per Employee
- -1.14M
- Employee Count
- 40
- Asset Turnover
- 0.11
- Inventory Turnover
- 0.62
Valuation Ratios
The current PE Ratio of SynCore Biotechnology Co., Ltd. is -0.01. SynCore Biotechnology Co., Ltd.’s PEG ratio is 0.00.
- PE Ratio
- -0.01
- PS Ratio
- 22.18
- PB Ratio
- 2.67
- Price to FCF
- -17.82
- Price to Operating Cash Flow
- -18.04
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, SynCore Biotechnology Co., Ltd. had revenue of 27.04M and earned -45.76M in profits. Earnings per share was -1300.00.
- Revenue
- 27.04M
- Gross Profit
- 21.09M
- Operating Income
- -47.20M
- Pretax Income
- -45.76M
- Net Income
- -45.76M
- EBITDA
- -29.62M
- Earnings Per Share (EPS)
- -1300.00
Cash Flow
In the last 12 months, operating cash flow was -32.41M and capital expenditures -238,000, giving a free cash flow of -32.65M billion.
- Operating Cash Flow
- -32.41M
- Free Cash Flow
- -32.65M
- Free Cash Flow per Share
- -0.92
Dividends & Yields
SynCore Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.61%
- Earnings Yield
- -8.01%
Stock Price Statistics
- Beta
- 0.42
- 52-Week Price Change
- -40.71%
- 50-Day Moving Average
- 18.00
- 200-Day Moving Average
- 19.81
- Relative Strength Index (RSI)
- 30.41
- Average Volume (3m)
- 14.83K
Important Dates
SynCore Biotechnology Co., Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
SynCore Biotechnology Co., Ltd. as a current ratio of 21.37, with Debt / Equity ratio of 0.85%
- Current Ratio
- 21.37
- Quick Ratio
- 20.41
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- 5.24
- Interest Coverage Ratio
- -272.81
Taxes
In the past 12 months, SynCore Biotechnology Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
SynCore Biotechnology Co., Ltd. EV to EBITDA ratio is -13.96, with an EV/FCF ratio of -13.96.
- EV to Sales
- 17.37
- EV to EBITDA
- -13.96
- EV to Free Cash Flow
- -13.96
- EV to Operating Cash Flow
- -14.06
Balance Sheet
SynCore Biotechnology Co., Ltd. has TWD 145.80M in cash and marketable securities with TWD 12.53M in debt, giving a net cash position of TWD 133.28M billion.
- Cash & Marketable Securities
- TWD 145.80M
- Total Debt
- TWD 12.53M
- Net Cash
- TWD 133.28M
- Net Cash Per Share
- TWD 3.89
- Tangible Book Value Per Share
- TWD 5.25
Margins
Gross margin is 81.41%, with operating margin of -194.10%, and net profit margin of -178.54%.
- Gross Margin
- 81.41%
- Operating Margin
- -194.10%
- Pretax Margin
- -178.54%
- Net Profit Margin
- -178.54%
- EBITDA Margin
- -124.48%
- EBIT Margin
- -191.25%
Analyst Forecast
The average price target for SynCore Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -1.68%
- EPS Growth Forecast
- -5.45%
